Description
Latin America cancer screening market
The Latin America cancer screening market is currently valued at USD 21.24 billion and is forecasted to achieve a growth rate of 7.19 % compound annual growth rate (CAGR) leading to a regional revenue of USD 30.06 Bn. Latin America’s growth is much slower compared to other regions. The region needs to work exclusively on its socio-economic and political framework to support the untapped growth of the cancer screening market.
By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The hospital and laboratory segment will witness a progressive growth during the forecast period 2018-2023. Independent physicians and clinics will witness a healthy growth rate of 6.28% during the forecast period 2018-2023.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and laboratory will be the leading segments during the forecast period 2018-2023 with biopsy witnessing a growth rate of 27.23% during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into Brazil, Colombia and the rest of Latin America.
Key growth factors
The rising prevalence of target disorders, an aging population, and the presence of favourable government initiatives for early disease diagnosis. There is increased support from the government in the form of awareness campaigns and performance-based reimbursements to contribute towards the growth of the cancer screening market.
Threats and key players
The region suffers from an imbalance in its socio-economic and political scenario which makes the services inaccessible. An informal and fragmented system will act as a major hurdle for the market while catering to the rising incidence of cancer cases.
Key players in the Latin America cancer screening market are Abbott diagnostics, Becton, Dickinson and Company, GE Healthcare, Roche Diagnostics and Hologic Inc.
What is covered in the report?
1. Overview of the Latin America cancer screening market.
2. Market drivers and challenges in the Latin America cancer screening market.
3. Market trends in the Latin America cancer screening market.
4. Historical, current and forecasted market size data for the Latin America market segmentation based on type of end users (Hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the Latin America market segmentation based on type of end users (Hospitals, laboratory, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of cancer screening market by countries and others (other parts of Europe) – by revenue
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the Latin American market.
Why buy?
o Understand the demand for cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services compared with the key players in the market.
Table of Contents
Chapter 1: Executive summary
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
Chapter 2: Latin America cancer screening market – market overview
2.1. Latin America market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
2.2. Latin America – market drivers and challenges
2.3. Value chain analysis – cancer screening market
2.4. Porter’s five forces analysis
2.5. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)
2.5. a. Hospitals – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Independent physicians and clinics revenue – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Growth drivers and key challenges
2.6. Market segmentation based on type of Screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.6. a. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Genetic – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Imaging – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d. Biopsy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e. Endoscopy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. f. Growth drivers and key challenges
2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.7. a. Lung – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. b. Breast – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. c. Melanoma – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. d. Kidney – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. e. Colorectal – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. f. Growth drivers and key challenges
2.8. Major country penetration
Chapter 3. Brazil cancer screening market
3.1. Brazil market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
3.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
3.2. a. Hospitals – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. b. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. c. Independent physicians and clinics revenue – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. d. Growth drivers and key challenges
3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.3. a. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. b. Genetic – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. c. Imaging – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. d. Biopsy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. e. Endoscopy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. f. Growth drivers and key challenges
3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.4. a. Lung – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. b. Breast – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. c. Melanoma – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. d. Kidney – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. e. Colorectal – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. f. Growth drivers and key challenges
Chapter 4. Colombia cancer screening market
4.1. Germany market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
4.2. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)
4.2. a. Hospitals – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. b. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. c. Independent physicians and clinics revenue – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. d. Growth drivers and key challenges
4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.3. a. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. b. Genetic – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. c. Imaging – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. d. Biopsy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. e. Endoscopy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. f. Growth drivers and key challenges
4.4. Market segmentation based on type application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.4. a. Lung – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. b. Breast – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. c. Melanoma – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. d. Kidney – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. e. Colorectal – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. f. Growth drivers and key challenges
Chapter 5. Others (the rest of Latin America) cancer screening market
5.1. Others (the rest of Latin America) market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
5.2. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)
5.2. a. Hospitals – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. b. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. c. Independent physicians and clinics revenue – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. d. Growth drivers and key challenges
5.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.3. a. Laboratory – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. b. Genetic – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. c. Imaging – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. d. Biopsy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. e. Endoscopy – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. f. Growth drivers and key challenges
5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.4. a. Lung – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. b. Breast – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. c. Melanoma – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. d. Kidney – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. e. Colorectal – Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. f. Growth drivers and key challenges
Chapter 6: Competitive landscape
6.1. Abbott diagnostics
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Becton, Dickinson and Company
6.2. a. Company snapshot
6.2. b. Product offerings
6.2. c. Growth strategies
6.2. d. Initiatives
6.2. e. Geographical presence
6.2. f. Key numbers
6.3. GE Healthcare
6.3. a. Company snapshot
6.3. b. Product offerings
6.3. c. Growth strategies
6.3. d. Initiatives
6.3. e. Geographical presence
6.3. f. Key numbers
6.4. Roche Diagnostics
6.4. a. Company snapshot
6.4. b. Product offerings
6.4. c. Growth strategies
6.4. d. Initiatives
6.4. e. Geographical presence
6.4. f. Key numbers
6.5. Hologic Inc.
6.5. a. Company snapshot
6.5. b. Product offerings
6.5. c. Growth strategies
6.5. d. Initiatives
6.5. e. Geographical presence
6.5. f. Key numbers
Chapter 7: Conclusion
Chapter 8: Appendix
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
